Advertisement

Erectile Dysfunction in the Setting of Prostate Cancer

  • Mary K. Samplaski
  • Kirk C. LoEmail author

Abstract

A diagnosis of prostate cancer (PCa) itself may negatively affect erectile function, as can the treatments. In addition, there are individual patient-related and psychological factors that may compromise erectile function in these men. Finally, PCa continues to be diagnosed in younger men, in whom potency preservation is an important consideration. Pretreatment erectile function, influenced by age, comorbidities, and psychological factors, is a predictor of posttreatment erectile function in men treated for PCa. Treatment-related factors may include intraoperative oncologic decisions and the postoperative course. Radiation, either in the form of brachytherapy or external beam, may have untoward effects on erectile function. The role of penile rehabilitation, as well as the optimal treatment protocol, remains undefined. It is clear that androgen deprivation therapy negatively impacts erections; conversely, the role of testosterone replacement in the setting of known PCa remains controversial. Sexual counseling is an important aspect of both therapy and prevention of ED in men with PCa. A more sophisticated understanding of the etiology of PCa-related ED will allow for more individualized therapy.

Keywords

Erectile dysfunction Prostate cancer Males Penile rehabilitation Radiotherapy 

References

  1. 1.
    Raina R, Pahlajani G, Agarwal A, Jones S, Zippe C. Long-term potency after early use of a vacuum erection device following radical prostatectomy. BJU Int. 2010;106:1719–22.PubMedCrossRefGoogle Scholar
  2. 2.
    Robinson JW, Moritz S, Fung T. Meta-analysis of rates of erectile function after treatment of localized prostate carcinoma. Int J Radiat Oncol Biol Phys. 2002;54:1063–8.PubMedCrossRefGoogle Scholar
  3. 3.
    NIH Consensus Conference. Impotence. NIH consensus development panel on impotence. JAMA. 1993;270:83–90.CrossRefGoogle Scholar
  4. 4.
    Merrill RM, Sloan A. Risk-adjusted incidence rates for prostate cancer in the United States. Prostate. 2012;72:181–5.PubMedCrossRefGoogle Scholar
  5. 5.
    Sidana A, Hernandez DJ, Feng Z, Partin AW, Trock BJ, Saha S, et al. Treatment decision-making for localized prostate cancer: what younger men choose and why. Prostate. 2012;72:58–64.PubMedCrossRefGoogle Scholar
  6. 6.
    Novara G, Ficarra V, D’Elia C, Secco S, De Gobbi A, Cavalleri S, et al. Preoperative criteria to select patients for bilateral nerve-sparing robotic-assisted radical prostatectomy. J Sex Med. 2010;7:839–45.PubMedCrossRefGoogle Scholar
  7. 7.
    Salomon G, Isbarn H, Budaeus L, Schlomm T, Briganti A, Steuber T, et al. Importance of baseline potency rate assessment of men diagnosed with clinically localized prostate cancer prior to radical prostatectomy. J Sex Med. 2009;6:498–504.PubMedCrossRefGoogle Scholar
  8. 8.
    Salonia A, Burnett AL, Graefen M, Hatzimouratidis K, Montorsi F, Mulhall JP, et al. Prevention and management of postprostatectomy sexual dysfunctions. Part 1: choosing the right patient at the right time for the right surgery. Eur Urol. 2012;62:261–72.PubMedCrossRefGoogle Scholar
  9. 9.
    Walz J, Perrotte P, Suardi N, Hutterer G, Jeldres C, Benard F, et al. Baseline prevalence of erectile dysfunction in a prostate cancer screening population. J Sex Med. 2008;5:428–35.PubMedCrossRefGoogle Scholar
  10. 10.
    Penson DF, McLerran D, Feng Z, Li L, Albertsen PC, Gilliland FD, et al. 5-year urinary and sexual outcomes after radical prostatectomy: results from the prostate cancer outcomes study. J Urol. 2008;179:S40–4.PubMedCrossRefGoogle Scholar
  11. 11.
    Kim DS, Chung YG, Kim DJ, Park KK, Chung MS, Lee DH, et al. Optimal timing to evaluate prediagnostic baseline erectile function in patients undergoing robot-assisted radical prostatectomy. J Sex Med. 2012;9:602–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Burnett AL, Aus G, Canby-Hagino ED, Cookson MS, D’Amico AV, Dmochowski RR, et al. Erectile function outcome reporting after clinically localized prostate cancer treatment. J Urol. 2007;178:597–601.PubMedCrossRefGoogle Scholar
  13. 13.
    Teloken P, Valenzuela R, Parker M, Mulhall J. The correlation between erectile function and patient satisfaction. J Sex Med. 2007;4:472–6.PubMedCrossRefGoogle Scholar
  14. 14.
    Briganti A, Gallina A, Suardi N, Capitanio U, Tutolo M, Bianchi M, et al. What is the definition of a satisfactory erectile function after bilateral nerve sparing radical prostatectomy? J Sex Med. 2011;8:1210–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Salonia A, Zanni G, Gallina A, Briganti A, Sacca A, Suardi N, et al. Unsuccessful investigation of preoperative sexual health issues in the prostate cancer “couple”: results of a real-life psychometric survey at a major tertiary academic center. J Sex Med. 2009;6:3347–55.PubMedCrossRefGoogle Scholar
  16. 16.
    Mulhall JP, Bella AJ, Briganti A, McCullough A, Brock G. Erectile function rehabilitation in the radical prostatectomy patient. J Sex Med. 2010;7:1687–98.PubMedCrossRefGoogle Scholar
  17. 17.
    Tal R, Alphs HH, Krebs P, Nelson CJ, Mulhall JP. Erectile function recovery rate after radical prostatectomy: a meta-analysis. J Sex Med. 2009;6:2538–46.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Briganti A, Gallina A, Suardi N, Capitanio U, Tutolo M, Bianchi M, et al. Predicting erectile function recovery after bilateral nerve sparing radical prostatectomy: a proposal of a novel preoperative risk stratification. J Sex Med. 2010;7:2521–31.PubMedCrossRefGoogle Scholar
  19. 19.
    Alemozaffar M, Regan MM, Cooperberg MR, Wei JT, Michalski JM, Sandler HM, et al. Prediction of erectile function following treatment for prostate cancer. JAMA. 2011;306:1205–14.PubMedCrossRefGoogle Scholar
  20. 20.
    Walsh PC, Donker PJ. Impotence following radical prostatectomy: insight into etiology and prevention. 1982. J Urol. 2002;167:1005–10.PubMedCrossRefGoogle Scholar
  21. 21.
    Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 2011;59:61–71.PubMedCrossRefGoogle Scholar
  22. 22.
    Masterson TA, Serio AM, Mulhall JP, Vickers AJ, Eastham JA. Modified technique for neurovascular bundle preservation during radical prostatectomy: association between technique and recovery of erectile function. BJU Int. 2008;101:1217–22.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Burnett AL. Rationale for cavernous nerve restorative therapy to preserve erectile function after radical prostatectomy. Urology. 2003;61:491–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Secin FP, Touijer K, Mulhall J, Guillonneau B. Anatomy and preservation of accessory pudendal arteries in laparoscopic radical prostatectomy. Eur Urol. 2007;51:1229–35.PubMedCrossRefGoogle Scholar
  25. 25.
    Hatzimouratidis K, Burnett AL, Hatzichristou D, McCullough AR, Montorsi F, Mulhall JP. Phosphodiesterase type 5 inhibitors in postprostatectomy erectile dysfunction: a critical analysis of the basic science rationale and clinical application. Eur Urol. 2009;55:334–47.PubMedCrossRefGoogle Scholar
  26. 26.
    Tal R, Valenzuela R, Aviv N, Parker M, Waters WB, Flanigan RC, et al. Persistent erectile dysfunction following radical prostatectomy: the association between nerve-sparing status and the prevalence and chronology of venous leak. J Sex Med. 2009;6:2813–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Mulhall JP, Slovick R, Hotaling J, Aviv N, Valenzuela R, Waters WB, et al. Erectile dysfunction after radical prostatectomy: hemodynamic profiles and their correlation with the recovery of erectile function. J Urol. 2002;167:1371–5.PubMedCrossRefGoogle Scholar
  28. 28.
    Mulhall J, Barnas J, Aviv N, Anderson M, Parker M. Sildenafil citrate response correlates with the nature and the severity of penile vascular insufficiency. J Sex Med. 2005;2:104–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Iacono F, Giannella R, Somma P, Manno G, Fusco F, Mirone V. Histological alterations in cavernous tissue after radical prostatectomy. J Urol. 2005;173:1673–6.PubMedCrossRefGoogle Scholar
  30. 30.
    Leungwattanakij S, Bivalacqua TJ, Usta MF, Yang DY, Hyun JS, Champion HC, et al. Cavernous neurotomy causes hypoxia and fibrosis in rat corpus cavernosum. J Androl. 2003;24:239–45.PubMedCrossRefGoogle Scholar
  31. 31.
    Hu WL, Hu LQ, Song J, Li SW, Zheng XM, Cheng B, et al. Fibrosis of corpus cavernosum in animals following cavernous nerve ablation. Asian J Androl. 2004;6:111–6.PubMedGoogle Scholar
  32. 32.
    Vignozzi L, Filippi S, Morelli A, Ambrosini S, Luconi M, Vannelli GB, et al. Effect of chronic tadalafil administration on penile hypoxia induced by cavernous neurotomy in the rat. J Sex Med. 2006;3:419–31.PubMedCrossRefGoogle Scholar
  33. 33.
    Potosky AL, Davis WW, Hoffman RM, Stanford JL, Stephenson RA, Penson DF, et al. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst. 2004;96:1358–67.PubMedCrossRefGoogle Scholar
  34. 34.
    Snyder KM, Stock RG, Buckstein M, Stone NN. Long-term potency preservation following brachytherapy for prostate cancer. BJU Int. 2012;110:221–5.PubMedCrossRefGoogle Scholar
  35. 35.
    Zelefsky MJ, Eid JF. Elucidating the etiology of erectile dysfunction after definitive therapy for prostatic cancer. Int J Radiat Oncol Biol Phys. 1998;40:129–33.PubMedCrossRefGoogle Scholar
  36. 36.
    van der Wielen GJ, Mulhall JP, Incrocci L. Erectile dysfunction after radiotherapy for prostate cancer and radiation dose to the penile structures: a critical review. Radiother Oncol. 2007;84:107–13.PubMedCrossRefGoogle Scholar
  37. 37.
    Akbal C, Tinay I, Simsek F, Turkeri LN. Erectile dysfunction following radiotherapy and brachytherapy for prostate cancer: pathophysiology, prevention and treatment. Int Urol Nephrol. 2008;40:355–63.PubMedCrossRefGoogle Scholar
  38. 38.
    Bottomley D, Ash D, Al-Qaisieh B, Carey B, Joseph J, St Clair S, et al. Side effects of permanent I125 prostate seed implants in 667 patients treated in Leeds. Radiother Oncol. 2007;82:46–9.PubMedCrossRefGoogle Scholar
  39. 39.
    Incrocci L, Slagter C, Slob AK, Hop WC. A randomized, double-blind, placebo-controlled, cross-over study to assess the efficacy of tadalafil (Cialis) in the treatment of erectile dysfunction following three-dimensional conformal external-beam radiotherapy for prostatic carcinoma. Int J Radiat Oncol Biol Phys. 2006;66:439–44.PubMedCrossRefGoogle Scholar
  40. 40.
    Incrocci L, Slob AK, Hop WC. Tadalafil (Cialis) and erectile dysfunction after radiotherapy for prostate cancer: an open-label extension of a blinded trial. Urology. 2007;70:1190–3.PubMedCrossRefGoogle Scholar
  41. 41.
    Pinkawa M, Gagel B, Piroth MD, Fischedick K, Asadpour B, Kehl M, et al. Erectile dysfunction after external beam radiotherapy for prostate cancer. Eur Urol. 2009;55:227–34.PubMedCrossRefGoogle Scholar
  42. 42.
    Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358:1250–61.PubMedCrossRefGoogle Scholar
  43. 43.
    Potters L, Torre T, Fearn PA, Leibel SA, Kattan MW. Potency after permanent prostate brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2001;50:1235–42.PubMedCrossRefGoogle Scholar
  44. 44.
    Incrocci L, Jensen PT. Pelvic radiotherapy and sexual function in men and women. J Sex Med. 2013;10 Suppl 1:53–64.PubMedCrossRefGoogle Scholar
  45. 45.
    Lehrer S, Cesaretti J, Stone NN, Stock RG. Urinary symptom flare after brachytherapy for prostate cancer is associated with erectile dysfunction and more urinary symptoms before implantation. BJU Int. 2006;98:979–81.PubMedCrossRefGoogle Scholar
  46. 46.
    Slater JD, Rossi Jr CJ, Yonemoto LT, Bush DA, Jabola BR, Levy RP, et al. Proton therapy for prostate cancer: the initial Loma Linda University experience. Int J Radiat Oncol Biol Phys. 2004;59:348–52.PubMedCrossRefGoogle Scholar
  47. 47.
    Kao J, Turian J, Meyers A, Hamilton RJ, Smith B, Vijayakumar S, et al. Sparing of the penile bulb and proximal penile structures with intensity-modulated radiation therapy for prostate cancer. Br J Radiol. 2004;77:129–36.PubMedCrossRefGoogle Scholar
  48. 48.
    Buyyounouski MK, Horwitz EM, Price RA, Hanlon AL, Uzzo RG, Pollack A. Intensity-modulated radiotherapy with MRI simulation to reduce doses received by erectile tissue during prostate cancer treatment. Int J Radiat Oncol Biol Phys. 2004;58:743–9.PubMedCrossRefGoogle Scholar
  49. 49.
    Peters CA, Stock RG, Cesaretti JA, Atencio DP, Peters S, Burri RJ, et al. TGFB1 single nucleotide polymorphisms are associated with adverse quality of life in prostate cancer patients treated with radiotherapy. Int J Radiat Oncol Biol Phys. 2008;70:752–9.PubMedCrossRefGoogle Scholar
  50. 50.
    Chung E, Brock GB. Emerging and novel therapeutic approaches in the treatment of male erectile dysfunction. Curr Urol Rep. 2011;12:432–43.PubMedCrossRefGoogle Scholar
  51. 51.
    Burnett AL, Allaf ME, Bivalacqua TJ. Erythropoietin promotes erection recovery after nerve-sparing radical retropubic prostatectomy: a retrospective analysis. J Sex Med. 2008;5:2392–8.PubMedCrossRefGoogle Scholar
  52. 52.
    Mulhall JP. Defining and reporting erectile function outcomes after radical prostatectomy: challenges and misconceptions. J Urol. 2009;181:462–71.PubMedCrossRefGoogle Scholar
  53. 53.
    Rabbani F, Schiff J, Piecuch M, Yunis LH, Eastham JA, Scardino PT, et al. Time course of recovery of erectile function after radical retropubic prostatectomy: does anyone recover after 2 years? J Sex Med. 2010;7:3984–90.PubMedCrossRefGoogle Scholar
  54. 54.
    Bannowsky A, Schulze H, van der Horst C, Seif C, Braun PM, Junemann KP. Nocturnal tumescence: a parameter for postoperative erectile integrity after nerve sparing radical prostatectomy. J Urol. 2006;175:2214–7.PubMedCrossRefGoogle Scholar
  55. 55.
    Mulhall JP, Bivalacqua TJ, Becher EF. Standard operating procedure for the preservation of erectile function outcomes after radical prostatectomy. J Sex Med. 2013;10:195–203.PubMedCrossRefGoogle Scholar
  56. 56.
    Tal R, Teloken P, Mulhall JP. Erectile function rehabilitation after radical prostatectomy: practice patterns among AUA members. J Sex Med. 2011;8:2370–6.PubMedCrossRefGoogle Scholar
  57. 57.
    Teloken P, Mesquita G, Montorsi F, Mulhall J. Post-radical prostatectomy pharmacological penile rehabilitation: practice patterns among the international society for sexual medicine practitioners. J Sex Med. 2009;6:2032–8.PubMedCrossRefGoogle Scholar
  58. 58.
    Musicki B, Burnett AL. eNOS function and dysfunction in the penis. Exp Biol Med. 2006;231:154–65.Google Scholar
  59. 59.
    Nehra A, Goldstein I, Pabby A, Nugent M, Huang YH, de las Morenas A, et al. Mechanisms of venous leakage: a prospective clinicopathological correlation of corporeal function and structure. J Urol. 1996;156:1320–9.PubMedCrossRefGoogle Scholar
  60. 60.
    Sirad F, Hlaing S, Kovanecz I, Artaza JN, Garcia LA, Rajfer J, et al. Sildenafil promotes smooth muscle preservation and ameliorates fibrosis through modulation of extracellular matrix and tissue growth factor gene expression after bilateral cavernosal nerve resection in the rat. J Sex Med. 2011;8:1048–60.PubMedPubMedCentralCrossRefGoogle Scholar
  61. 61.
    Montorsi F, Brock G, Lee J, Shapiro J, Van Poppel H, Graefen M, et al. Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy. Eur Urol. 2008;54:924–31.PubMedCrossRefGoogle Scholar
  62. 62.
    Padma-Nathan H, McCullough AR, Levine LA, Lipshultz LI, Siegel R, Montorsi F, et al. Randomized, double-blind, placebo-controlled study of postoperative nightly sildenafil citrate for the prevention of erectile dysfunction after bilateral nerve-sparing radical prostatectomy. Int J Impot Res. 2008;20:479–86.PubMedCrossRefGoogle Scholar
  63. 63.
    Bannowsky A, Schulze H, van der Horst C, Hautmann S, Junemann KP. Recovery of erectile function after nerve-sparing radical prostatectomy: improvement with nightly low-dose sildenafil. BJU Int. 2008;101:1279–83.PubMedCrossRefGoogle Scholar
  64. 64.
    Gallina A, Ferrari M, Suardi N, Capitanio U, Abdollah F, Tutolo M, et al. Erectile function outcome after bilateral nerve sparing radical prostatectomy: which patients may be left untreated? J Sex Med. 2012;9:903–8.PubMedCrossRefGoogle Scholar
  65. 65.
    Garcia-Cardoso J, Vela R, Mahillo E, Mateos-Caceres PJ, Modrego J, Macaya C, et al. Increased cyclic guanosine monophosphate production and endothelial nitric oxide synthase level in mononuclear cells from sildenafil citrate-treated patients with erectile dysfunction. Int J Impot Res. 2010;22:68–76.PubMedCrossRefGoogle Scholar
  66. 66.
    Salonia A, Burnett AL, Graefen M, Hatzimouratidis K, Montorsi F, Mulhall JP, et al. Prevention and management of postprostatectomy sexual dysfunctions part 2: recovery and preservation of erectile function, sexual desire, and orgasmic function. Eur Urol. 2012;62:273–86.PubMedCrossRefGoogle Scholar
  67. 67.
    Incrocci L, Koper PC, Hop WC, Slob AK. Sildenafil citrate (Viagra) and erectile dysfunction following external beam radiotherapy for prostate cancer: a randomized, double-blind, placebo-controlled, cross-over study. Int J Radiat Oncol Biol Phys. 2001;51:1190–5.PubMedCrossRefGoogle Scholar
  68. 68.
    Incrocci L, Hop WC, Slob AK. Efficacy of sildenafil in an open-label study as a continuation of a double-blind study in the treatment of erectile dysfunction after radiotherapy for prostate cancer. Urology. 2003;62:116–20.PubMedCrossRefGoogle Scholar
  69. 69.
    Schiff JD, Bar-Chama N, Cesaretti J, Stock R. Early use of a phosphodiesterase inhibitor after brachytherapy restores and preserves erectile function. BJU Int. 2006;98:1255–8.PubMedCrossRefGoogle Scholar
  70. 70.
    Mulhall J, Land S, Parker M, Waters WB, Flanigan RC. The use of an erectogenic pharmacotherapy regimen following radical prostatectomy improves recovery of spontaneous erectile function. J Sex Med. 2005;2:532–40. discussion 40–2.PubMedCrossRefGoogle Scholar
  71. 71.
    Park DL, Aron M, Rewcastle JC, Boyd SD, Gill IS. A model for managing erectile dysfunction following prostate cancer treatment. Curr Opin Urol. 2013;23:129–34.PubMedCrossRefGoogle Scholar
  72. 72.
    Kohler TS, Pedro R, Hendlin K, Utz W, Ugarte R, Reddy P, et al. A pilot study on the early use of the vacuum erection device after radical retropubic prostatectomy. BJU Int. 2007;100:858–62.PubMedCrossRefGoogle Scholar
  73. 73.
    Vardi Y, Appel B, Jacob G, Massarwi O, Gruenwald I. Can low-intensity extracorporeal shockwave therapy improve erectile function? A 6-month follow-up pilot study in patients with organic erectile dysfunction. Eur Urol. 2010;58:243–8.PubMedCrossRefGoogle Scholar
  74. 74.
    Aoki H, Nagao J, Ueda T, Strong JM, Schonlau F, Yu-Jing S, et al. Clinical assessment of a supplement of Pycnogenol® and L-arginine in Japanese patients with mild to moderate erectile dysfunction. Phytother Res. 2012;26:204–7.PubMedCrossRefGoogle Scholar
  75. 75.
    Ledda A, Belcaro G, Cesarone MR, Dugall M, Schonlau F. Investigation of a complex plant extract for mild to moderate erectile dysfunction in a randomized, double-blind, placebo-controlled, parallel-arm study. BJU Int. 2010;106:1030–3.PubMedCrossRefGoogle Scholar
  76. 76.
    Stanislavov R, Nikolova V, Rohdewald P. Improvement of seminal parameters with Prelox: a randomized, double-blind, placebo-controlled, cross-over trial. Phytother Res. 2009;23:297–302.PubMedCrossRefGoogle Scholar
  77. 77.
    Stanislavov R, Nikolova V. Treatment of erectile dysfunction with pycnogenol and L-arginine. J Sex Marital Ther. 2003;29:207–13.PubMedCrossRefGoogle Scholar
  78. 78.
    Montague DK. Penile prosthesis implantation for end-stage erectile dysfunction after radical prostatectomy. Rev Urol. 2005;7 Suppl 2:S51–7.PubMedPubMedCentralGoogle Scholar
  79. 79.
    Tal R, Jacks LM, Elkin E, Mulhall JP. Penile implant utilization following treatment for prostate cancer: analysis of the SEER-Medicare database. J Sex Med. 2011;8:1797–804.PubMedCrossRefGoogle Scholar
  80. 80.
    Menard J, Tremeaux JC, Faix A, Pierrevelcin J, Staerman F. Erectile function and sexual satisfaction before and after penile prosthesis implantation in radical prostatectomy patients: a comparison with patients with vasculogenic erectile dysfunction. J Sex Med. 2011;8:3479–86.PubMedCrossRefGoogle Scholar
  81. 81.
    Tefilli MV, Dubocq F, Rajpurkar A, Gheiler EL, Tiguert R, Barton C, et al. Assessment of psychosexual adjustment after insertion of inflatable penile prosthesis. Urology. 1998;52:1106–12.PubMedCrossRefGoogle Scholar
  82. 82.
    Deho F, Salonia A, Briganti A, Zanni G, Gallina A, Rokkas K, et al. Anatomical radical retropubic prostatectomy in patients with a preexisting three-piece inflatable prosthesis: a series of case reports. J Sex Med. 2009;6:578–83.PubMedCrossRefGoogle Scholar
  83. 83.
    Choi KH, Lee SH, Jung WS, Chung BH. Robot-assisted radical prostatectomy in a patient with a preexisting three-piece inflatable penile prosthesis. Korean J Urol. 2010;51:70–2.PubMedPubMedCentralCrossRefGoogle Scholar
  84. 84.
    Ramsawh HJ, Morgentaler A, Covino N, Barlow DH, DeWolf WC. Quality of life following simultaneous placement of penile prosthesis with radical prostatectomy. J Urol. 2005;174:1395–8.PubMedCrossRefGoogle Scholar
  85. 85.
    Khera M. Androgens and erectile function: a case for early androgen use in postprostatectomy hypogonadal men. J Sex Med. 2009;6 Suppl 3:234–8.PubMedCrossRefGoogle Scholar
  86. 86.
    Morelli A, Filippi S, Mancina R, Luconi M, Vignozzi L, Marini M, et al. Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. Endocrinology. 2004;145:2253–63.PubMedCrossRefGoogle Scholar
  87. 87.
    Morelli A, Corona G, Filippi S, Ambrosini S, Forti G, Vignozzi L, et al. Which patients with sexual dysfunction are suitable for testosterone replacement therapy? J Endocrinol Investig. 2007;30:880–8.CrossRefGoogle Scholar
  88. 88.
    Kim SC, Song C, Kim W, Kang T, Park J, Jeong IG, et al. Factors determining functional outcomes after radical prostatectomy: robot-assisted versus retropubic. Eur Urol. 2011;60:413–9.PubMedCrossRefGoogle Scholar
  89. 89.
    Agarwal PK, Oefelein MG. Testosterone replacement therapy after primary treatment for prostate cancer. J Urol. 2005;173:533–6.PubMedCrossRefGoogle Scholar
  90. 90.
    Khera M, Grober ED, Najari B, Colen JS, Mohamed O, Lamb DJ, et al. Testosterone replacement therapy following radical prostatectomy. J Sex Med. 2009;6:1165–70.PubMedCrossRefGoogle Scholar
  91. 91.
    Leibowitz RL, Dorff TB, Tucker S, Symanowski J, Vogelzang NJ. Testosterone replacement in prostate cancer survivors with hypogonadal symptoms. BJU Int. 2010;105:1397–401.PubMedCrossRefGoogle Scholar
  92. 92.
    Pastuszak AW, Pearlman AM, Lai WS, Godoy G, Sathyamoorthy K, Liu JS, et al. Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy. J Urol. 2013;190:639–44.PubMedPubMedCentralCrossRefGoogle Scholar
  93. 93.
    Wilke DR, Parker C, Andonowski A, Tsuji D, Catton C, Gospodarowicz M, et al. Testosterone and erectile function recovery after radiotherapy and long-term androgen deprivation with luteinizing hormone-releasing hormone agonists. BJU Int. 2006;97:963–8.PubMedCrossRefGoogle Scholar
  94. 94.
    Teloken PE, Ohebshalom M, Mohideen N, Mulhall JP. Analysis of the impact of androgen deprivation therapy on sildenafil citrate response following radiation therapy for prostate cancer. J Urol. 2007;178:2521–5.PubMedCrossRefGoogle Scholar
  95. 95.
    Dale W, Bilir P, Han M, Meltzer D. The role of anxiety in prostate carcinoma: a structured review of the literature. Cancer. 2005;104:467–78.PubMedPubMedCentralCrossRefGoogle Scholar
  96. 96.
    Bill-Axelson A, Garmo H, Lambe M, Bratt O, Adolfsson J, Nyberg U, et al. Suicide risk in men with prostate-specific antigen-detected early prostate cancer: a nationwide population-based cohort study from PCBaSe Sweden. Eur Urol. 2010;57:390–5.PubMedCrossRefGoogle Scholar
  97. 97.
    Fang F, Keating NL, Mucci LA, Adami HO, Stampfer MJ, Valdimarsdottir U, et al. Immediate risk of suicide and cardiovascular death after a prostate cancer diagnosis: cohort study in the United States. J Natl Cancer Inst. 2010;102:307–14.PubMedCrossRefGoogle Scholar
  98. 98.
    Helfand BT, Glaser AP, Rimar K, Zargaroff S, Hedges J, McGuire BB, et al. Prostate cancer diagnosis is associated with an increased risk of erectile dysfunction after prostate biopsy. BJU Int. 2013;111:38–43.PubMedCrossRefGoogle Scholar
  99. 99.
    Klotz L. Active surveillance for favorable-risk prostate cancer: background, patient selection, triggers for intervention, and outcomes. Curr Urol Rep. 2012;13:153–9.PubMedCrossRefGoogle Scholar
  100. 100.
    Salonia A, Gallina A, Zanni G, Briganti A, Deho F, Sacca A, et al. Acceptance of and discontinuation rate from erectile dysfunction oral treatment in patients following bilateral nerve-sparing radical prostatectomy. Eur Urol. 2008;53:564–70.PubMedCrossRefGoogle Scholar
  101. 101.
    Titta M, Tavolini IM, Dal Moro F, Cisternino A, Bassi P. Sexual counseling improved erectile rehabilitation after non-nerve-sparing radical retropubic prostatectomy or cystectomy—results of a randomized prospective study. J Sex Med. 2006;3:267–73.PubMedCrossRefGoogle Scholar
  102. 102.
    Canada AL, Neese LE, Sui D, Schover LR. Pilot intervention to enhance sexual rehabilitation for couples after treatment for localized prostate carcinoma. Cancer. 2005;104:2689–700.PubMedCrossRefGoogle Scholar
  103. 103.
    Incrocci L. Talking about sex to oncologists and cancer to sexologists. J Sex Med. 2011;8:3251–3.PubMedCrossRefGoogle Scholar
  104. 104.
    Stead ML, Fallowfield L, Brown JM, Selby P. Communication about sexual problems and sexual concerns in ovarian cancer: qualitative study. BMJ. 2001;323:836–7.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.Department of Surgery, Institute of UrologyUniversity of Southern CaliforniaLos AngelesUSA
  2. 2.Division of Urology, Department of Surgery, Mount Sinai Hospital, Faculty of Medicine, Institute of Medical ScienceUniversity of TorontoTorontoCanada

Personalised recommendations